DiaKine Therapeutics - Diabetes Solutions

Include Page

Product Pipeline | Research | News/Information | About DiaKine | Investor Relations

DiaKine Therapeutics, Inc. is a development-stage company commercializing novel immune modulators such as Lisofylline (LSF) and related oral compounds into therapies for diabetes and related complications. These drugs have the potential to stop the progression of diabetes and reverse damage already caused by the disease.

Therapeutics under development by DiaKine include:

· Adjunct to islet cell transplants

· Halt the progression of type 1 diabetes in newly diagnosed adults.

· Treatment and prevention of Latent Autoimmune Diabetes of Adults (LADA).

· Treatment and prevention of insulin requiring type 2 diabetic

· Treatment and prevention of diabetes complications

For more information, please contact us at info@diakine.com.

Congratulations to Dr. Jerry Nadler on being named a Pfizer Visiting Professor in Diabetes. This program facilitates in-depth, educationally focused visits by prominent medical experts to U.S. medical schools and/or teaching hospitals. These unrestricted educational grants are nationally competitive, and grant recipients are chosen by an independent Academic Advisory Board of recognized leaders in diabetes medicine.

01/22/2009
DiaKine Drug Improves Type 2 Insulin Action; Reduces Harm of Fat in Preclinical Study (read story)

DiaKine Therapeutics’ Lead Compound in Phase 2 Clinical Trial (read story)

DiaKine Therapeutics • 1414 Sachem Place • Suite 3 • Charlottesville, VA 22901 • 434-975-2001